Loading...
Loading...
DBTX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 14.1M |
| Operating I/L | -14.1M |
| Other Income/Expense | 0.9M |
| Interest Income | 0.9M |
| Pretax | -13.2M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -13.3M |
Decibel Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing innovative treatments for hearing and balance disorders. The company's focus areas include gene therapies for congenital, monogenic hearing loss, hair cell regeneration, and otoprotection therapeutics. Their lead gene therapy product candidate, DB-OTO, aims to restore hearing in individuals with profound hearing loss due to otoferlin gene mutations. Additionally, they are developing gene therapy programs to address balance disorders, prevent cisplatin-induced hearing loss, and restore hearing in individuals with specific genetic deficiencies. Decibel Therapeutics has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for congenital hearing loss.
